{
    "nctId": "NCT01711801",
    "officialTitle": "A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.",
    "inclusionCriteria": "* Healthy male volunteers, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, serology and urinalysis\n* Body mass index (BMI) 18 to 30 kg/m2 inclusive\n* Male subjects (whether surgically sterilized or not) with female partners of child-bearing potential must use two forms of contraception, one of which must be a barrier method, for the duration of the study and for 77 days after the last dose\n* Must be MALE\n* Must have minimum age of 18 Years\n* Must have maximum age of 45 Years",
    "exclusionCriteria": "* History or presence of any clinically significant disease or disorder\n* Any condition or disease that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the investigator\n* History of clinically significant hypersensitivity or allergic drug reactions\n* Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse\n* Regular smoker (\\> 5 cigarettes, \\> 1 pipeful or \\> 1 cigar per day)\n* Positive for hepatitis B, hepatitis C or HIV infection\n* Dietary restrictions that would prohibit the consumption of standardized meals\n* Participation in an investigational drug or device study within 90 days prior to screening, as calculated from the follow-up from the previous study"
}